Centro de Investigación del Cáncer-Universidad de Salamanca
Centro de Investigación del Cáncer-Universidad de Salamanca is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
Sponsor Oncomatryx Biopharma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
Sponsor Oncomatryx Biopharma S.L.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Centro de Investigación del Cáncer-Universidad de Salamanca?
The 2026-10-09 snapshot links Centro de Investigación del Cáncer-Universidad de Salamanca to 2 distinct CTIS trials. Recorded services include biomarkers detection (OMTX705 pharmacodynamics profiling). These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Centro de Investigación del Cáncer-Universidad de Salamanca?
The most frequently recorded therapeutic areas are Gastroenterology, Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Centro de Investigación del Cáncer-Universidad de Salamanca conducted?
The linked trials record locations in 1 country, including Spain. These are trial locations, not confirmed office locations or countries where Centro de Investigación del Cáncer-Universidad de Salamanca delivered services.
What can this page tell me about Centro de Investigación del Cáncer-Universidad de Salamanca's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Centro de Investigación del Cáncer-Universidad de Salamanca. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Centro de Investigación del Cáncer-Universidad de Salamanca